Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

EGF receptor tyrosine kinase inhibitor selected for clinical testing at Parke-Davis

March 16, 2000

NIH advisory committee approves phase III protocol for Introgen's p53 gene therapy

March 15, 2000

Orphan Medical's Busulfex approved in Israel

March 15, 2000

Additional mechanism of action revealed for Neovastat

March 15, 2000

Alizyme receives notice of allowance, manufacturing license for mucositis product

March 14, 2000

New compounds for cancer developed at Abbott

March 14, 2000

Oxigene and Techniclone join forces to develop new-generation anticancer agents

March 14, 2000

Distamycin used as lead at P&U to design new alkylating agents

March 13, 2000

AEterna cleared to commence phase III trial of AE-941 for treatment of kidney cancer

March 13, 2000

Malignant melanoma antisense compound enters pivotal trials

March 13, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 14, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...